Comparison of neurogenic effects of fluoxetine, duloxetine and running in mice.
Hippocampal neurogenesis can be regulated by extrinsic factors, such as exercise and antidepressants. While there is evidence that the selective serotonin reuptake inhibitor (SSRI) fluoxetine enhances neurogenesis, the new dual serotonergic-noradrenergic reuptake inhibitor (SNRI) duloxetine has not been evaluated in this context. In addition, it is unclear whether effects of antidepressants and running on cell genesis and behavior are of similar magnitude in mice. Here, we assessed neurogenesis and open-field behavior in 2-month-old female C57Bl/6 mice after 28days of treatment with either fluoxetine (18mg/kg), duloxetine (2, 6 or 18mg/kg) or exercise. New cell survival, as measured by 5-bromo-2'-deoxyuridine (BrdU)-labeled cells, was enhanced by 200% in the running group only. Both running and fluoxetine, but not duloxetine, increased the percentage of new cells that became neurons. In the open-field test, animals treated with either drug spent less time in the center than controls and runners. In addition, fluoxetine treatment resulted in reduced locomotor activity. Together, these data show that the neurogenic response to exercise is much stronger than to antidepressants and imply a low likelihood that anxiolytic effects of these drugs are mediated by adult neurogenesis in C57Bl/6 mice.
Marlatt
Michael W
MW
Swammerdam Institute for Life Science-Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.
Lucassen
Paul J
PJ
van Praag
Henriette
H
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D000068736:Duloxetine Hydrochloride; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology*; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D055495:Neurogenesis / Q000187:drug effects / Q000502:physiology; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D010805:Physical Conditioning, Animal / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013876:Thiophenes / Q000494:pharmacology*
D000068736:Duloxetine Hydrochloride; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes
Neurosci Lett. 2001 Jul 27;308(1):25-8
11445277
J Gend Specif Med. 1998 Sep;1(1):21-7
11279849
Nat Neurosci. 1999 Mar;2(3):266-70
10195220
Neuromolecular Med. 2008;10(2):128-40
18286389
Mol Psychiatry. 2009 Sep;14(9):856-64
19139747
J Gend Specif Med. 2000 Mar-Apr;3(2):54-8
11253247
Acta Physiol Scand. 1989 Sep;137(1):1-13
2678895
Neuroscience. 2009 Oct 6;163(2):609-17
19576966
Curr Pharm Des. 2005;11(12):1475-93
15892657
Eur Neuropsychopharmacol. 2010 Jan;20(1):1-17
19748235
Nat Rev Neurosci. 2001 May;2(5):343-51
11331918
Pharmacol Biochem Behav. 2002 Apr;71(4):667-80
11888558
Pharmacol Biochem Behav. 2006 Sep;85(1):44-9
16920181
Neuron. 2002 Mar 28;34(1):13-25
11931738
Neuron. 2009 May 28;62(4):479-93
19477151
J Neurosci. 2000 Dec 15;20(24):9104-10
11124987
Am J Psychiatry. 2003 Aug;160(8):1516-8
12900317
J Neurosci. 2008 Feb 6;28(6):1374-84
18256257
Psychosom Med. 2007 Sep-Oct;69(7):587-96
17846259
J Comp Neurol. 2005 May 23;486(1):39-47
15834963
Arch Gen Psychiatry. 1987 Jan;44(1):69-76
2432848
Nature. 1995 Jan 12;373(6510):109
7816089
J Comp Neurol. 2008 Aug 1;509(4):372-81
18512685
Hippocampus. 2009 Oct;19(10):928-36
19212941
Neuroscience. 2000;101(2):305-12
11074154
Nat Rev Drug Discov. 2005 Sep;4(9):764-74
16121130
Brain Res. 2008 Sep 4;1228:14-9
18616933
Neuropsychopharmacology. 2009 May;34(6):1523-32
19020498
J Neurosci. 1997 Apr 1;17(7):2492-8
9065509
Eur J Neurosci. 2007 Dec;26(12):3395-401
18052970
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13427-31
10557337
Psychopharmacology (Berl). 2009 May;203(4):753-62
19104776
Neuropsychopharmacology. 2007 Nov;32(11):2351-9
17327885
Neuroscience. 2007 Feb 9;144(3):1033-44
17137724
J Neurosci. 1996 Mar 15;16(6):2027-33
8604047
Nat Neurosci. 2007 Sep;10(9):1110-5
17726477
J Neurosci. 2009 Nov 18;29(46):14484-95
19923282
Neuron. 2008 Aug 14;59(3):399-412
18701066
J Abnorm Psychol. 1998 Feb;107(1):109-17
9505043
Neuropsychopharmacology. 2004 Jul;29(7):1321-30
15085085
Mol Psychiatry. 2000 May;5(3):262-9
10889528
J Pharmacol Exp Ther. 2010 Jan;332(1):266-73
19828877
Behav Brain Res. 2008 Sep 1;192(1):42-60
18468702
Trends Neurosci. 2002 Jun;25(6):295-301
12086747
Eur Arch Psychiatry Clin Neurosci. 2007 Aug;257(5):250-60
17401728
Science. 2003 Aug 8;301(5634):805-9
12907793
Am J Psychiatry. 2005 Jun;162(6):1179-87
15930067
Annu Rev Neurosci. 1999;22:105-22
10202533
Eur Arch Psychiatry Neurol Sci. 1985;235(3):171-8
3879219
Trends Cogn Sci. 2009 Nov;13(11):456-63
19819753
Clin Psychol Rev. 2001 Feb;21(1):33-61
11148895
J Manag Care Pharm. 2007 Nov;13(9 Suppl A):S3-11
18062736
Behav Brain Res. 2009 Jan 30;197(1):31-40
18722480
Mol Psychiatry. 2008 Feb;13(2):119-21
18202694
Neuropsychopharmacology. 2008 May;33(6):1312-22
17609676
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11032-7
11005874